mCRPC patients are, particularly, characterized by expression of high levels of prostate-specific membrane antigen (PSMA) in their prostate tumor and its related metastatic tissues [3], and therefore, the [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT) that effectively targets PSMA receptors is meanwhile successfully applied in such patients. The gene discussed is FOLH1; the disease is prostate neoplasm.